Last updated: May 30, 2026
Executive summary: ASCLERA (fixed-dose combination of losartan, hydrochlorothiazide, and a third component depending on market labeling) requires identifying (1) the finished-dose manufacturer that produces ASCLERA tablets and (2) the upstream API and key intermediate suppliers for each component. No verifiable sourcing dataset was provided to map specific, named suppliers (by company and facility) to ASCLERA, so a complete supplier profile cannot be produced from the available information.
What companies supply the drug ASCLERA for wholesalers and pharmacies?
No supplier list is provided in the input. A supplier answer requires specific, named entities tied to ASCLERA’s marketing authorization (finished-dose site) and each API (or API intermediate) producer chain.
Who is the finished-dose manufacturer of ASCLERA in the US/EU?
Finished-dose supplier identification typically comes from:
- FDA label “Manufactured for/By” section (US)
- EMA product information (EU)
- Orange Book (if listed as an NDA drug product)
- GMP inspection/DMF-linked manufacturing sites
None of these are provided.
Which firms supply the APIs for ASCLERA components?
API suppliers are normally sourced from:
- DMFs tied to each active ingredient
- Orange Book active ingredient listings
- EP/US DMF public data
None of these are provided.
What suppliers provide the losartan, hydrochlorothiazide, and third-component APIs used in ASCLERA?
No component mapping for “ASCLERA” is provided in the input, and the “third component” cannot be confirmed. Without the exact formulation composition and label-strength, an accurate API supplier map cannot be constructed.
Do API suppliers differ by dosage strength or manufacturing site?
Yes. Sourcing often changes across strengths, batches, and regulatory filings (site-of-manufacture variation in:
- Drug product NDA/BLA supplements
- DMF updates
- contract manufacturing transitions)
No strength/site information is provided.
How do key intermediate suppliers affect supply reliability?
Key intermediates drive:
- lead-time risk
- impurity control
- compliance with process validation
No intermediate list is provided.
What is the Orange Book status of ASCLERA, and does it list the labeled manufacturer suppliers?
To answer supplier questions using the Orange Book, the drug must have:
- an NDA/BLA number
- active ingredient listings
- listed drug (RLD) and applicant/holder
- patent and exclusivity linkages
None of those identifiers are provided.
What patent and exclusivity landscape limits who can supply ASCLERA generics?
This requires:
- identifying ASCLERA’s RLD
- mapping listed patents and expiration dates
- checking whether any Paragraph IV filings exist
No patent identifiers are provided.
Which suppliers are involved in authorized generics or supply agreements for ASCLERA?
Authorized generics and supply licensing depend on:
- the RLD holder’s supply strategy
- any granted authorization agreements
No holder, agreement, or regulatory pathway information is provided.
What generic entry risks exist if ASCLERA APIs are sourced from limited suppliers?
This depends on:
- single-source vs multi-source API availability
- DMF concentration
- geographic supply concentration
No supplier base or sourcing structure is provided.
Key Takeaways
- A supplier profile requires ASCLERA’s exact composition, strength(s), and regulatory identifiers (US label/NDA or EU marketing authorization).
- The input contains no company names, label manufacturing language, DMF identifiers, or Orange Book entries, so no verified supplier mapping can be produced.
FAQs
- How do I identify the finished-dose manufacturer listed on the ASCLERA label?
- Where can ASCLERA API DMF-linked manufacturing sites be found?
- Does ASCLERA have multiple suppliers across dosage strengths?
- Which databases show ASCLERA RLD and applicant/holder for supplier mapping?
- How do manufacturing site changes appear in FDA supplements or DMF updates?
References
No sources were cited because no ASCLERA-specific regulatory or composition data was provided in the input.
